LY3437943
Also known as LY3437943 — this name points to Retatrutide in our directory.
About Retatrutide
A once-weekly GLP-1/GIP/glucagon receptor triple agonist in late-stage trials for obesity—next-gen metabolic peptide drug.
Retatrutide activates three incretin-related pathways, producing large weight loss in phase 2 trials (SURMOUNT-1 and related studies). It is not yet widely approved like semaglutide or tirzepatide. Prescription-only when approved; compounding or research sourcing carries the same risks as other unapproved GLP-1 mimics.
Where you will see LY3437943
LY3437943 is a prescription drug brand—not a cosmetic INCI name or bulk research powder. The active molecule is Retatrutide. Dosing, indications, and side effects come from the FDA label and your clinician, not peptide forum stacks.
Compare Retatrutide
Other names
LY3437943
Triple agonist
Common questions
Is LY3437943 the same as Retatrutide?
Yes. LY3437943 is a brand or nickname that refers to Retatrutide in our directory—the same active molecule, different packaging or marketing name.
What is Retatrutide?
A once-weekly GLP-1/GIP/glucagon receptor triple agonist in late-stage trials for obesity—next-gen metabolic peptide drug. Retatrutide activates three incretin-related pathways, producing large weight loss in phase 2 trials (SURMOUNT-1 and related studies). It is not yet widely approved like semaglutide or tirzepatide. Prescription-only when approved; compounding or research sourcing carries the same risks as other unapproved GLP-1 mimics.
How do I find LY3437943 on a label?
No. LY3437943 is a prescription medicine dispensed through pharmacies with a clinician—not a peptide powder or cosmetic serum you buy by alias alone.